These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 33830688)
1. [SGLT2 inhibitors, new option to prevent or treat heart failure]. Scheen AJ; Lancellotti P Rev Med Liege; 2021 Apr; 76(4):248-255. PubMed ID: 33830688 [TBL] [Abstract][Full Text] [Related]
2. [Role of SGLT2 inhibitors (gliflozins) in heart failure]. Scheen AJ; Ancion A; Lancellotti P Rev Med Suisse; 2022 Aug; 18(792):1546-1550. PubMed ID: 36004654 [TBL] [Abstract][Full Text] [Related]
3. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652 [TBL] [Abstract][Full Text] [Related]
4. [Dapagliflozin in DELIVER : confirmation of the benefit with SGLT2 inhibitors in heart failure with preserved ejection fraction]. Scheen A; Lancellotti P Rev Med Liege; 2023 Feb; 78(2):79-84. PubMed ID: 36799324 [TBL] [Abstract][Full Text] [Related]
5. [SGLT2 inhibitors in patients with chronic kidney disease : from clinical trials to guidelines and new prospects for clinical practice]. Scheen AJ; Delanaye P Rev Med Liege; 2021 Mar; 76(3):186-194. PubMed ID: 33682388 [TBL] [Abstract][Full Text] [Related]
6. Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review. Mentz RJ; Brunton SA; Rangaswami J Cardiovasc Diabetol; 2023 Nov; 22(1):316. PubMed ID: 37974185 [TBL] [Abstract][Full Text] [Related]
7. Sodium-glucose co-transporter-2 inhibitors eligibility in patients with heart failure with reduced ejection fraction. Monzo L; Ferrari I; Cicogna F; Tota C; Calò L Int J Cardiol; 2021 Oct; 341():56-59. PubMed ID: 34454968 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. Packer M; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Anker SD; Zannad F; Eur J Heart Fail; 2019 Oct; 21(10):1270-1278. PubMed ID: 31584231 [TBL] [Abstract][Full Text] [Related]
9. Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Non-Diabetic Chronic Kidney Disease. Mima A Adv Ther; 2021 May; 38(5):2201-2212. PubMed ID: 33860925 [TBL] [Abstract][Full Text] [Related]
10. SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR? Raschi E; Fadini GP; Diemberger I; Poluzzi E; De Ponti F Expert Opin Pharmacother; 2021 Apr; 22(5):647-650. PubMed ID: 33141609 [No Abstract] [Full Text] [Related]
11. Dapagliflozin in a Real-World Chronic Heart Failure Population: How Many Are Actually Eligible? Maltês S; Cunha GJL; Rocha BML; Presume J; Guerreiro R; Henriques C; Rodrigues C; Araújo I; Fonseca C Cardiology; 2021; 146(2):201-206. PubMed ID: 33524984 [TBL] [Abstract][Full Text] [Related]
12. When and How to Use Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction or Chronic Kidney Disease. O'Meara E; Verma S Can J Cardiol; 2021 Apr; 37(4):669-673. PubMed ID: 33450364 [TBL] [Abstract][Full Text] [Related]
13. Counteracting heart failure with diabetes drugs: a review into the pharmacokinetic and pharmacodynamic properties. Scheen AJ Expert Opin Drug Metab Toxicol; 2022 Jun; 18(6):381-393. PubMed ID: 35876091 [TBL] [Abstract][Full Text] [Related]
14. The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review. Scheen AJ Expert Rev Endocrinol Metab; 2023; 18(4):271-282. PubMed ID: 37154218 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. Anker SD; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Zannad F; Packer M; Eur J Heart Fail; 2019 Oct; 21(10):1279-1287. PubMed ID: 31523904 [TBL] [Abstract][Full Text] [Related]
17. Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. Seferović PM; Fragasso G; Petrie M; Mullens W; Ferrari R; Thum T; Bauersachs J; Anker SD; Ray R; Çavuşoğlu Y; Polovina M; Metra M; Ambrosio G; Prasad K; Seferović J; Jhund PS; Dattilo G; Čelutkiene J; Piepoli M; Moura B; Chioncel O; Ben Gal T; Heymans S; de Boer RA; Jaarsma T; Hill L; Lopatin Y; Lyon AR; Ponikowski P; Lainščak M; Jankowska E; Mueller C; Cosentino F; Lund L; Filippatos GS; Ruschitzka F; Coats AJS; Rosano GMC Eur J Heart Fail; 2020 Sep; 22(9):1495-1503. PubMed ID: 32618086 [TBL] [Abstract][Full Text] [Related]
18. Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion. Packer M Cardiovasc Diabetol; 2019 Oct; 18(1):129. PubMed ID: 31585532 [TBL] [Abstract][Full Text] [Related]